Sleep-Wake Disorders

One patient, one frightening night he doesn’t remember. He wants off the drug the FDA singled out — but the question the team is actually arguing is whether the boxed warning names the real hazard, or just the drug that happened to get studied.

Two patients, same diagnosis, same guideline recommending therapy before drugs. What actually determines whether either of them gets offered that choice has less to do with the evidence than with what’s reachable from where they’re sitting.

A patient starting insomnia treatment for the first time, with insurance that will cover either drug. The disagreement isn’t about which drug works — it’s about whether being newer, and mechanistically different, is itself a reason to reach for one first.

Nine years on the same drug, no dose escalation, no adverse events — and a flat refusal to try the therapy every guideline says should have come first. The disagreement is about what “working” actually obligates anyone to do next.

The drug he’s about to be handed has never been FDA-evaluated for the thing it’s about to be prescribed for. That fact alone doesn’t settle whether it’s the right choice — but it’s the fact everyone in the room has to reckon with before agreeing to it.

The same molecule, the same bottle label at two very different strengths — one dose an antidepressant, the other a genuinely different, FDA-approved sleep drug. The case for confusion here is real, and so is the case for why it matters.

A new narcolepsy diagnosis, and a genuine choice between two real first-line options — complicated by exactly the kind of history that makes one of them a harder sell than the textbook comparison usually admits.

The most effective drug for her cataplexy is, chemically, the same compound once better known as a club drug and a date-rape agent. The disagreement isn’t about efficacy — it’s about how much of that history belongs in the conversation, and how much of it is just baggage.

She’s tired of setting a 2 a.m. alarm for her second dose. The newer formulation would fix exactly that — but it isn’t a straightforward upgrade, because the convenience and the cardiovascular trade-off don’t point the same direction for a woman with her specific risk profile.

He has been taking more and more melatonin, later and later, chasing a bigger dose right before bed. The actual fix required moving the same modest dose to a completely different clock time — several hours earlier, not stronger.

The medication decision here is close to routine. What the team actually argues about is a harder question the diagnosis itself raises — one that has nothing to do with the prescription pad.

Both patients have the same violent-dream diagnosis clonazepam is built for. What changes the answer isn’t the diagnosis — it’s what else is true about each of them by the time they reach this age.

Her symptoms are worse, and spreading to her arms — the intuitive read is that her restless legs syndrome is simply progressing. It isn’t. The drug treating it is very likely the thing making it worse.

A resident reaches for the drug that was first-line for two decades. The attending stops her — not because the drug fails to work, but because it works today at the cost of a problem that tends to arrive later.

Her bloodwork came back normal, by the standard her primary doctor was taught to use. It isn’t normal by the threshold that actually matters for what she has — and that gap nearly meant starting a drug she didn’t need yet.

His apnea is fixed, by every number that matters. What CPAP hasn’t fixed is falling asleep behind the wheel — a real, separate problem with real, separate drugs, neither of which is simply “more CPAP.”

The drug is real, the approval is real, and the trial data is genuinely impressive — but it took a full year to produce, and she can’t tolerate the mask that’s supposed to protect her airway until then. The disagreement is about what fills that gap.